🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

493 results for “Regeneron UK Limited” Clear

  1. Dupilumab

    Regeneron UK Limited

    Allergic Contact Dermatitis

    approved small molecule active

    1 trial

  2. Dupilumab

    Regeneron UK Limited

    Keloid

    approved small molecule completed

    2 trials

  3. Dupilumab

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    approved small molecule active

    1 trial

  4. Dupilumab

    Regeneron UK Limited

    Dermal Hypersensitivity Reaction

    approved small molecule completed

    1 trial

  5. Dupilumab

    Regeneron UK Limited

    Dermatitis, Atopic

    approved small molecule active

    5 trials

  6. Dupilumab

    Regeneron UK Limited

    Atopic Dermatitis (AD)

    approved small molecule terminated

    2 trials

  7. Dupilumab

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule active

    16 trials

  8. Dupilumab

    Regeneron UK Limited

    Asthma

    approved small molecule active

    13 trials

  9. Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

    Regeneron UK Limited

    Eosinophilic Esophagitis (EoE)

    approved small molecule active

    1 trial

  10. Dupilumab Injectable Product

    Regeneron UK Limited

    Asthma

    approved small molecule active

    1 trial

  11. Dupilumab Only Product

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule active

    1 trial

  12. Dupilumab Prefilled Syringe

    Regeneron UK Limited

    Nasal Polyps

    approved small molecule active

    1 trial

  13. Dupilumab SAR231893

    Regeneron UK Limited

    Dermatitis Atopic

    approved small molecule completed

    2 trials

  14. Dupilumab SAR231893

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule completed

    1 trial

  15. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Rhinosinusitis With Nasal Polyps

    approved small molecule completed

    1 trial

  16. Dupixent

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule active

    1 trial

  17. Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Degeneration

    approved small molecule completed

    1 trial

  18. Intravitreal Aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    approved small molecule terminated

    2 trials

  19. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Cystoid Macular Edema

    approved small molecule completed

    1 trial

  20. Intravitreal Aflibercept Injection (IAI)

    Regeneron UK Limited

    Chorioretinal Vascular Disease

    approved small molecule completed

    1 trial

  21. Intravitreal Aflibercept Injection (IAI)

    Regeneron UK Limited

    Age - Related Macular Degeneration (AMD)

    approved small molecule completed

    1 trial

  22. Intravitreal Aflibercept Injection 2mg

    Regeneron UK Limited

    Neovascular Age-related Macular Degeneration

    approved small molecule active

    2 trials

  23. Intravitreal aflibercept injection

    Regeneron UK Limited

    Macular Degeneration

    approved small molecule completed

    1 trial

  24. Intravitreal aflibercept injection 2.0mg

    Regeneron UK Limited

    Polypoidal Choroidal Vasculopathy

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources